Phase 1 Intravenous Study of INCA036873 for Adults with Advanced Solid Tumors and Blood Cancers

What this Trial Is About

Researchers are evaluating the safety and tolerability of INCA036873 in adults with advanced solid tumors and blood cancers, including specific types such as clear cell renal cell carcinoma and various lymphomas. This Phase 1 study aims to understand how the drug behaves in the body and its effects on disease over time. Participants receive INCA036873 through intravenous infusion at doses defined by the study protocol. The study includes different parts dose escalation to find safe dosing levels, dose expansion to further assess safety and activity, and a pharmacodynamic cohort to evaluate drug effects on the body. These parts are sequential and all involve administration of the drug. During the study, participants will have regular monitoring for side effects, disease response, and how the drug is processed by the body. Assessments include tracking dose-limiting toxicities up to 28 days, treatment-related adverse events for up to about two years, and pharmacokinetic measurements. Participants may be followed closely with scans, laboratory tests, and other evaluations to observe disease control and response duration.

A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies